icosapent ethyl / Generic mfg. - LARVOL DELTA

Trends in utilization and cost of triglyceride-lowering therapies among Medicare beneficiaries: An analysis from the Medicare part D database. (PubMed, Am J Prev Cardiol) - "We used the Medicare Part D Prescriber dataset from 2013 to 2021 to identify all generic and brand name formulations of triglyceride-lowering therapies (fibrates, omega-3 acid ethyl esters, and niacin)...These trends likely reflect changes in the evidence base and guideline recommendations for hypertriglyceridemia treatment. While most beneficiaries received generic medications when available, substantial spending on brand name medications persists, indicating potential missed opportunities for cost savings."

Journal • Medicare • Reimbursement • US reimbursement • Atherosclerosis • Cardiovascular • Dyslipidemia • Hypertriglyceridemia

BEYOND CARDIOVASCULAR BENEFITS: HEMOPTYSIS LINKED TO ICOSAPENT ETHYL THERAPY (CHEST 2025) - "While the precise mechanism of Icosapent ethyl cardiovascular benefits remains unclear, it has been associated with an increased risk of bleeding (12%), particularly in patients concurrently taking antithrombotic agents like aspirin, clopidogrel, or warfarin. While the REDUCE-IT trial demonstrated an increased bleeding risk with Icosapent ethyl, this did not translate into a higher incidence of fatal bleeding events, such as hemorrhagic stroke or severe gastrointestinal bleeding. The bleeding risk may be attributed to Icosapent ethyl's potential antithrombotic properties, which could affect platelet function clotting mechanisms. Clinicians should exercise caution when prescribing Icosapent ethyl, especially in patients with a history bleeding or those on concurrent anticoagulant therapy."

Cardiovascular • Cerebral Hemorrhage • Cough • Dyslipidemia • Gastroenterology • Hematological Disorders • Hypertriglyceridemia • Infectious Disease • Pneumonia • Respiratory Diseases • Severe Hypertriglyceridemia

ERUPTIVE XANTHOMA AS A SIGN OF SEVERE HYPERTRIGLYCERIDEMIA (CHEST 2025) - "Endocrinology restarted fenofibrate and initiated icosapent ethyl, atorvastatin, and ezetimibe. Eruptive xanthomatosis is a key clinical marker of severe hypertriglyceridemia. Early recognition and aggressive lipid-lowering therapy can prevent complications such as acute pancreatitis without the need for plasmapheresis."

Crohn's disease • Diabetes • Dyslipidemia • Endocrine Disorders • Gastroenterology • Genetic Disorders • Hypertriglyceridemia • Immunology • Inflammatory Bowel Disease • Nephrology • Obesity • Pancreatitis • Renal Disease • Severe Hypertriglyceridemia • Type 2 Diabetes Mellitus • LPL

A data-driven mathematical model for evaluating the societal and economic burden of delayed access to innovative medicines. (PubMed, AIMS Public Health) - "The proposed model incorporated mortality probabilities through the Heligman-Pollard (HP) model, examining how delays influence health outcomes, particularly for patients awaiting treatments like Icosapent ethyl...By ensuring completeness, consistency, and reliability in healthcare data, the framework advocates for evidence-based policy decisions that promote equitable healthcare access and minimize disparities. The present study underscores the importance of efficient pharmaceutical policymaking in maximizing the societal benefits of innovative treatments, ensuring that both health outcomes and economic sustainability are prioritized in healthcare systems."

HEOR • Journal

Stima dei pazienti potenzialmente eleggibili alla terapia con icosapent etile in Italia mediante revisione dei dati di letteratura. (PubMed, Glob Reg Health Technol Assess) - No abstract available

Journal • Review • Cardiovascular • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders

Icosapent ethyl-induced lipoprotein remodeling and its impact on cardiovascular disease risk markers in normolipidemic individuals. (PubMed, JCI Insight) - "Of the pro-atherogenic properties tested, IPE significantly reduced apoB lipoprotein binding to proteoglycans, which correlated with lower apoB particle concentration, cholesterol content, and specific lipid species in LDL, including phosphatidylcholine 38:3 previously associated with CVD.CONCLUSIONThese findings highlight IPE's rapid, uniform remodeling of lipoproteins and reduced proteoglycan binding, likely contributing to previously observed CVD risk reduction. Persistent interindividual lipidome signatures underscore the potential for personalized therapeutic approaches in atherosclerotic CVD treatment.TRIAL REGISTRATIONNCT04152291.FUNDINGJenny and Antti Wihuri Foundation, Research Council of Finland, Sigrid Jusélius Foundation, Finnish Foundation for Cardiovascular Research, Emil Aaltonen Foundation, Ida Montin Foundation, Novo Nordisk Foundation, Finnish Cultural Foundation, and Jane and Aatos Erkko Foundation."

Biomarker • Journal • Atherosclerosis • Cardiovascular • APOB

Prevention of Heart Failure With Icosapent Ethyl Results in Cost-Savings in the Spanish Population With Established Cardiovascular Disease. (PubMed, Value Health Reg Issues) - "This study demonstrated that the use of icosapent ethyl in patients at high risk for cardiovascular diseases with established cardiovascular disease will result in cost savings in Spanish hospitals, as the benefits of preventing heart failure outweigh the acquisition costs of icosapent ethyl."

HEOR • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Efficacy of Icosapent Ethyl for Cardiovascular Risk Reduction by Aspirin Use in REDUCE-IT (AHA 2025) - "Available on Sunday, November 09, 2025 at 03:15pm CDT."

Clinical • Cardiovascular

Icosapent Ethyl in Patients With and Without Atrial Fibrillation (REDUCE IT) (AHA 2025) - No abstract available

Clinical • Atrial Fibrillation • Cardiovascular

Serial Coronary CTA for Monitoring Response to Lipid-Lowering Therapy: A Narrative Review. (PubMed, Curr Atheroscler Rep) - "This review summarizes current evidence on the use of serial coronary computed tomography angiography (CCTA) to monitor the effects of lipid-lowering therapies (LLTs)-including statins, PCSK9 inhibitors, and icosapent ethyl-on coronary plaque regression...Serial CCTA is a valuable noninvasive tool for monitoring the effects of LLTs on coronary plaque progression aiding in risk stratification. However, wider clinical adoption is limited by cost, radiation exposure, contrast-related risks, and technical challenges in some patient populations."

Journal • Review • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease

SALVAGE: IcoSApent ethyL to Slow Down Aortic VAlve Stenosis proGrEssion (clinicaltrials.gov) - P2 | N=110 | Active, not recruiting | Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular

EPA&LDL: The Effect of E-EPA on Circulating LDL and Plasma Lipid Metabolism (clinicaltrials.gov) - P=N/A | N=68 | Completed | Sponsor: Wihuri Research Institute | Unknown status ➔ Completed | N=50 ➔ 68 | Trial completion date: Dec 2020 ➔ Dec 2024

Enrollment change • Trial completion • Trial completion date • Atherosclerosis • Cardiovascular • Dyslipidemia • Metabolic Disorders

Benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-IT. (PubMed, Eur J Prev Cardiol) - P3 | "IPE significantly reduced MI across most subtypes and sizes in statin-treated patients with elevated triglycerides at increased cardiovascular risk."

Journal • Atrial Fibrillation • Cardiovascular • Diabetes • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders • Myocardial Infarction

Cost-utility analysis of icosapent ethyl in patients with high triglyceride levels and recent acute coronary syndrome in Catalonia. (PubMed, J Med Econ) - "IPE appears to be a cost-effective intervention for high-risk patients with elevated TG and recent ACS in Catalonia. While limitations related to model assumptions, data extrapolation, and partial adaptation to local clinical practice exist, the findings remain consistent with international evidence and suggest that IPE could be a cost-effective intervention in Catalonia, offering a valuable opportunity to optimize healthcare resource allocation in the management of high-risk CV populations."

HEOR • Journal • Acute Coronary Syndrome • Cardiovascular • Dyslipidemia • Hypertriglyceridemia

Successful Rituximab Treatment of GPIHBP1 Autoantibody-Associated Hypertriglyceridemia. (PubMed, JACC Case Rep) - "GPIHBP1-AAS-associated hypertriglyceridemia should be recognized and can be successfully treated with rituximab."

Journal • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders • Pancreatitis • Severe Hypertriglyceridemia • APOA5

Overlapping Method of Use Patents to Prevent Generic Entry. (PubMed, J Law Med Ethics) - "Case studies of icosapent ethyl (Vascepa) and sacubitril-valsartan (Entresto) illustrate how overlapping use codes delay generic entry, inflate costs, and limit patient access. Reforms are needed to improve FDA and USPTO oversight of use code assignments and clarify legal standards for induced infringement, which would preserve the balance between rewarding innovation and ensuring timely access to affordable medicines."

Journal

Expected value of implementation of icosapent ethyl in Sweden. (PubMed, BMC Health Serv Res) - No abstract available

Journal • Cardiovascular

Bempedoic acid in clinical practice. (ESC-WCC 2025) - "The majority had coronary artery disease (91.5%) and preserved left ventricular function (72%).The most commonly used statin was rosuvastatin (60.7%), followed by atorvastatin (33.9%)...Additionally, 7.3% were taking icosapent ethyl...ConclusionsBempedoic acid is a valuable tool for lowering LDL cholesterol and preventing cardiovascular events, especially in patients who cannot tolerate statins or do not reach target levels. Its efficacy and safety, achieving LDL reductions of around 18% demonstrated both in clinical trials and increasingly in clinical practice, as well as the possibility of taking it in a single pill with ezetimibe, position it as an important therapeutic option in the current management of dyslipidaemia."

Clinical • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Hypertension • CRP

Optimizing lipid control after acute coronary syndrome: can we strike early and strong in real-world practice? (ESC-WCC 2025) - " The protocol was implemented at discharge after ACS hospitalization and included an early stepwise approach with rapid escalation using high-potency statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, icosapent ethyl, or even fibrates when necessary. Implementing an early intensive lipid-lowering protocol at ACS discharge is feasible, even in the absence of a dedicated rehabilitation unit. Significant lipid control can be safely achieved within eight weeks, although financial constraints represent the main limitation."

Clinical • Real-world • Real-world evidence • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Heart Failure

Efficacy of icosapent ethyl across the spectrum of baseline triglyceride glucose indices (EASD 2025) - P3 | "Among patients with elevated triglycerides who have diabetes with risk factors or CVD, higher baseline TyG indices indicated increasing CV risk. Icosapent ethyl reduced CVD rates irrespective of baseline TyG index."

Clinical • Diabetes • Hypertriglyceridemia • Metabolic Disorders

IPE eligibility post-ACS: Clarifying treatment gaps and refining lipid-based risk assessment. (PubMed, Int J Cardiol) - No abstract available

Journal • Acute Coronary Syndrome • Cardiovascular

Eicosapentaenoic acid (EPA) inhibited lipoprotein(a) [Lp(a)] oxidation and its effects on expression of oxidative stress and pro-inflammatory proteins in endothelial cells (ESC-WCC 2025) - "The omega-3 fatty acid eicosapentaenoic acid (EPA) delivered as icosapent ethyl (4 g/d) reduced CV events in high-risk patients with elevated Lp(a) (REDUCE-IT)... EPA attenuated Lp(a) oxidation and its effects on oxidative stress and pro-inflammatory protein expression. Inhibition of Lp(a) oxidation by EPA may thereby reduce endothelial dysfunction and inflammation in the presence of elevated Lp(a), thereby contributing to the reduction of CV events in patients with elevated Lp(a) levels."

Oxidative stress • Cardiovascular • APOB • HMOX1 • ICAM1 • PPARG

Icosapent ethyl eligible patients following acute coronary syndrome are at increased risk of myocardial re-infarction: Data from CALLINICUS-Hellas registry (ESC-WCC 2025) - "In a series of contemporary ACS patients, IPE might be considered in one out of four patients shortly after the index event. IPE eligible patients are more likely to have adverse cardiometabolic features and are at increased risk for recurrent MI."

Clinical • Acute Coronary Syndrome • Cardiovascular • Dyslipidemia • Hypertension • Myocardial Infarction

Direct analysis of pharmaceutical tablets using dielectric barrier discharge ionization-mass spectrometry: An ambient mass spectrometry approach (ACS-Fall 2025) - "The aim of the study is to quickly determine and quantify active pharmaceutical ingredients (APIs) in intact tablets, such as paracetamol, ramoril, clonazepam, icosapent ethyl, pantoprazole, atorvastatin and cholecalciferol (vitamin D3), without requiring a lot of sample preparation. The method has the potential to be used in the pharmaceutical industries for both quality control and counterfeit identification because it can identify contaminants or degradation products and differentiate between authentic and counterfeit drugs. This work advances the area of ambient mass spectrometry by highlighting the adaptability of DBDI-MS as an affordable, high-throughput tool for the direct analysis of solid pharmaceutical tablets."

Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM (ESC-WCC 2025) - "In REDUCE-IT secondary prevention patients, the CKM syndrome was associated with incremental CVD risk compared with MetS without diabetes and normal renal function. IPE treatment further reduced CVD risk in patients with CKM, thereby supporting a role for this therapy in affected patients. ."

Cardiovascular • Dyslipidemia